The US Multi-Society Task Force recently released new recommendations for colorectal cancer (CRC) screenings. Since there has been an increase in CRC among younger Americans, while incidences in those over age 50 is decreasing, the recommendations consider the importance of systematic screening tests even for people without any CRC symptoms.
The US Multi-Society Task Force (MSTF) recently released new recommendations for colorectal cancer (CRC) screenings. Beginning at age 50, the MSTF suggests participating in colonoscopies and fecal immunochemical testing (FIT), as these screening tests can identify cancer and pre-cancerous growths. Early detection of cancer ultimately increases the success of treatments.
The task force periodically updates its recommendations as new evidence becomes available. The MSTF recently noticed an increase in CRC among younger Americans, while incidences of CRC in those over age 50 is decreasing. Therefore, the recommendations consider the importance of systematic screening tests even for people without any CRC symptoms.
"We believe these recommendations make the presentation of screening options in the office easier for providers and patients, maximizing both effectiveness and adherence,” lead author Douglas K. Rex, MD, FASGE, AGAF, MACG, said in a statement. “The document also addresses important issues for organized screening programs that are sometimes used in large health plans.”
The task force ranked screening tests while considering the strength of the recommendation, test availability, cost, current usage patterns, implementation obstacles, and the likelihood that the patients will retake the test when necessary.
Tier 1 of screening tests include a colonoscopy every 10 years or an annual FIT. Tier 2 screening options include a computed tomography colonography every 5 years, a FIT-fecal DNA every 3 years, or a flexible sigmoidoscopy every 5 to 10 years. Tier 3 option is a capsule colonoscopy every 5 years.
Following the rankings, the MSTF included specific screening recommendations for those with a family history of CRC.
“People with a family history of CRC in a first-degree relative diagnosed before age 60 should undergo colonoscopy every 5 years, beginning at age 40 or 10 years before the age at which their relative was diagnosed, whichever comes first,” the task force noted. “People with one first-degree relative diagnosed at age 60 or older are advised to begin screening at age 40.”
MSTF’s recommendations also consider the evidence of rising incidence of CRC in the African American population. Because of this, the new MSTF document recommends that screening should begin age 45 due the high CRC rates and lower survival rates among African-Americans as opposed to other races.
"These recommendations constitute a practical approach toward the ultimate goal of maximizing screening rates, while using well accepted, effective and cost-effective tests," concluded Rex.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Combatting Misconceptions of Clinical Trials to Improve Patient Participation
October 16th 2024There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Read More
Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage
October 15th 2024Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Read More